KRAS and leukoencephalopathy with calcifications and cysts: Generally speaking, KRAS mutation is a negative predictor of survival.30 Wang et al. showed that the five‐year survival rate of patients with KRAS mutations in LCC was lower than that of wild‐type (25.4% vs. 47.8%, P = 0.028).11 Studies on KRAS mutations have made progress.